Sugi Predict

Sugi Predict / Targets / ERCC4

ERCC4

DNA repair endonuclease XPF (EC 3.1.-.-) (DNA · Q92889 · ERCC4 on Sugi Atlas →

16,538 patent compounds predicted against ERCC4, 10,712 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL107237 SCHEMBL107237 0.81 15/20
SCHEMBL175299 SCHEMBL175299 0.66 15/20
SCHEMBL107288 SCHEMBL107288 0.66 15/20
SCHEMBL339753 SCHEMBL339753 0.59 14/20
SCHEMBL107165 SCHEMBL107165 0.73 13/20
SCHEMBL107880 SCHEMBL107880 0.60 12/20
SCHEMBL108637 SCHEMBL108637 0.60 12/20
SCHEMBL141914 SCHEMBL141914 0.60 12/20
SCHEMBL108628 SCHEMBL108628 0.79 11/20
SCHEMBL108102 SCHEMBL108102 0.82 10/20
SCHEMBL107157 SCHEMBL107157 0.76 9/20
SCHEMBL108218 SCHEMBL108218 0.78 8/20
SCHEMBL912290 SCHEMBL912290 0.47 8/20
SCHEMBL898314 SCHEMBL898314 0.59 7/20
SCHEMBL1421097 SCHEMBL1421097 0.43 7/20
SCHEMBL138689 SCHEMBL138689 0.56 6/20
SCHEMBL108018 SCHEMBL108018 0.55 5/20
SCHEMBL42351 SCHEMBL42351 0.48 5/20
SCHEMBL1143282 SCHEMBL1143282 0.61 4/20
SCHEMBL851008 SCHEMBL851008 0.60 4/20

Clinical trials — most relevant to ERCC4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer PHASE2UNKNOWN
Satraplatin and Prednisone to Treat Prostate Cancer PHASE2COMPLETED
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer PHASE2COMPLETED
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction PHASE2COMPLETED
Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer PHASE2WITHDRAWN
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy PHASE2COMPLETED
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer PHASE2COMPLETED
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer PHASE2COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer PHASE2WITHDRAWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Olaparib in People With Malignant Mesothelioma PHASE2COMPLETED
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer PHASE1COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Immunohistochemical Expression of Excision Repair Cross Complementation Group 1 (ERCC1) in Laryngeal Squamous Cell Carcinoma and Its Correlation With Response to Radiotherapy. nanUNKNOWN
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome nanUNKNOWN
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel nanCOMPLETED
Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or Trichothiodystrophy nanCOMPLETED
Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum nanCOMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews nanCOMPLETED
Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate nanCOMPLETED
Genetics of Prostate Cancer in Young Patients nanCOMPLETED
XPAND Trial: Enhancing XP Photoprotection Activities - New Directions nanCOMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581 nanCOMPLETED
Natural History Study for DNA Repair Disorders nanRECRUITING
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a ERCC4 binder may also engage these)

ProteinNameSimilarity
Q9QYM7 — 1.000 Q9QYM7 →
Q9QZD4 — 1.000 Q9QZD4 →
Q6NYU2 — 0.978 Q6NYU2 →
Q9H269 — 0.977 Q9H269 →
Q5E9L7 — 0.976 Q5E9L7 →
Q8BPM2 — 0.975 Q8BPM2 →
Q8QFR2 — 0.974 Q8QFR2 →
MAP4K5 Mitogen-activated protein kinase kinase kinase kinase 5 0.974 landscape →
E9Q4Z2 — 0.974 E9Q4Z2 →
Q920Q4 — 0.974 Q920Q4 →
Q5RGJ5 — 0.972 Q5RGJ5 →
P82922 — 0.972 P82922 →
O00291 — 0.972 O00291 →
Q5ZJV4 — 0.971 Q5ZJV4 →
Q60HG1 — 0.971 Q60HG1 →
Q9SV20 — 0.971 Q9SV20 →
Q5R8R4 — 0.971 Q5R8R4 →
P49135 — 0.971 P49135 →
Q9ER88 — 0.971 Q9ER88 →
Q91W86 — 0.971 Q91W86 →
P97789 — 0.971 P97789 →
P23116 — 0.970 P23116 →
Q641Y5 — 0.970 Q641Y5 →
Q7ZY60 — 0.970 Q7ZY60 →
Q6DFF4 — 0.970 Q6DFF4 →
Q1RMT1 — 0.970 Q1RMT1 →
Q6P4T2 — 0.970 Q6P4T2 →
Q5ZKK7 — 0.970 Q5ZKK7 →
A4GWN3 — 0.970 A4GWN3 →
Q7ZVV1 — 0.970 Q7ZVV1 →